Note 12. Commitments

Leases

The Company’s adoption of ASU No. 2016-02 resulted in an increase in the Company’s assets and liabilities of $7.9 million at July 1, 2019. In the first quarter of Fiscal 2020, the Company recorded a ROU lease asset totaling $1.2 million related to an existing lease at Cody Labs upon adoption of ASU No. 2016-02. The Company subsequently recorded a full impairment of the asset as a result of the decision to cease operations at Cody Labs. At December 31, 2019, the Company has a ROU lease asset of $6.0 million and a ROU liability of $7.2 million, of which $1.8 million and $5.4 million represent the current and non-current balance, respectively.

The Company recently signed an eight year lease for its new headquarters in Trevose, Pennsylvania. The Company will provide lease improvements prior to the lease commencement date, which is anticipated to be during the fourth quarter of Fiscal 2020. As of December 31, 2019, per ASC Topic 842, Leases, the Company has not recorded a ROU lease asset and liability related to the lease of its new headquarters since the lease has not commenced.

Components of lease cost are as follows:


	Three Months Ended		Six Months Ended
(In thousands)	December 31, 2019		December 31, 2019
Operating lease cost	$	590	$	1,071
Variable lease cost		32		61
Short-term lease cost (a)		124		279
Total	$	746	$	1,411

(a)

Not recorded on the Consolidated Balance Sheet.

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:


	Six Months Ended
(In thousands)	December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	966
Non-cash activity:
ROU assets obtained in exchange for new operating lease liabilities	$	—

Weighted-average remaining lease term and discount rate for our operating leases are as follows:


	Six Months Ended
	December 31, 2019
Weighted-average remaining lease term	9	years
Weighted-average discount rate	7.50	%

Maturities of lease liabilities by fiscal year for our operating leases are as follows:


(In thousands)	Amounts Due
2020	$	975
2021		1,487
2022		1,169
2023		1,169
2024		1,169
Thereafter		3,929
Total lease payments		9,898
Less: Imputed interest		2,692
Present value of lease liabilities	$	7,206

As of June 30, 2019, future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) for the twelve-month periods ending June 30 thereafter are as follows:


(In thousands)	Amounts Due
2020	$	1,898
2021		1,450
2022		1,123
2023		1,123
2024		1,123
Thereafter		3,839
Total	$	10,556

Other Commitment

During the third quarter of Fiscal 2017, the Company signed an agreement with a company operating in the pharmaceutical business, under which the Company agreed to provide up to $15.0 million in revolving loans, which expires in seven years and bears interest at 2.0%, for the purpose of expansion and other business needs. The decision to provide any portion of the revolving loan is at the Company’s sole discretion. Prior to the first quarter of Fiscal 2019, the Company had the option to convert the first $7.5 million into a 50% ownership interest in the entity. The board of the entity is comprised of five members, one of which is an employee of the Company.

In the first quarter of Fiscal 2019, the Company sold 50% of the outstanding loan to a third party for $5.6 million and, in addition to assigning 50% of all right, title and interest in the loan and loan documents, the Company relinquished its right to convert a portion of the outstanding loan balance to an equity interest in the entity. As of December 31, 2019, $6.4 million was outstanding under the revolving loan and is included in other assets. Based on the guidance set forth in ASC 810-10 Consolidation, the Company has concluded that it has a variable interest in the entity. However, the Company is not the primary beneficiary to the entity and as such, is not required to consolidate the entity’s results of operations.

In the second quarter of Fiscal 2020, the Company executed a License and Collaboration Agreement with North South Brother Pharmacy Investment Co., Ltd. and HEC Group PTY, Ltd. (collectively, “HEC”) to develop an insulin glargine product that would be biosimilar to Lantus Solostar. Under the terms of the deal, among other things, the Company shall fund up to the initial $32 million of the development costs and split 50/50 any development costs in excess thereof. Lannett shall receive an exclusive license to distribute and market the product in the United States upon FDA approval under the 50/50 profit split for the first ten years following commercialization, followed by a 60/40 split in favor of HEC for the following five years.